Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
102.48 USD | +1.33% | +0.79% | -7.63% |
Financials (USD)
Sales 2023 * | 59.92 B | Sales 2024 * | 63.03 B | Capitalization | 260 B |
---|---|---|---|---|---|
Net income 2023 * | 630 M | Net income 2024 * | 18.75 B | EV / Sales 2023 * | 4,80x |
Net Debt 2023 * | 27.72 B | Net Debt 2024 * | 15.62 B | EV / Sales 2024 * | 4,37x |
P/E ratio 2023 * | 359x | P/E ratio 2024 * | 13,5x | Employees | 68,000 |
Yield 2023 * | 2,88% | Yield 2024 * | 3,16% | Free-Float | 70.80% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +1.33% | ||
1 week | +0.79% | ||
1 month | -0.21% | ||
3 months | -5.96% | ||
6 months | -7.18% | ||
Current year | -7.63% |
1 week
99.80
102.69

1 month
99.80
105.17

Current year
96.36
119.65

1 year
96.36
119.65

3 years
70.89
119.65

5 years
65.25
119.65

10 years
45.69
119.65

Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 56 | 2014 |
Director of Finance/CFO | 54 | 1989 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 54 | 2020 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 2007 |
Pamela Craig
BRD | Director/Board Member | 65 | 2015 |
Inge Thulin
BRD | Director/Board Member | 69 | 2018 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 323 M€ | -5.37% | - | |
7.37% | 18 M€ | -8.94% | - | |
7.20% | 212 M€ | +8.58% |
Date | Price | Change | Volume |
---|---|---|---|
23-11-30 | 102.48 | +1.33% | 29,299,666 |
23-11-29 | 101.13 | +0.95% | 10,286,779 |
23-11-28 | 100.18 | -1.23% | 8,738,483 |
23-11-27 | 101.43 | -0.43% | 7,356,536 |
23-11-24 | 101.87 | +0.19% | 3,167,952 |
Delayed Quote Nyse, November 30, 2023 at 04:02 pm EST
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-02-01
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
BUY
Number of Analysts
30
Last Close Price
102.48USD
Average target price
123.61USD
Spread / Average Target
+20.62%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.63% | 256 B $ | |
+61.56% | 532 B $ | |
+48.29% | 452 B $ | |
-12.45% | 366 B $ | |
-11.89% | 245 B $ | |
-18.74% | 217 B $ | |
+1.83% | 199 B $ | |
-9.73% | 197 B $ | |
-40.53% | 170 B $ | |
+2.64% | 143 B $ |